宣泰医药(688247.SH)：西格列汀二甲双胍缓释片新增规格获批准

Core Viewpoint - The company announced that its wholly-owned subsidiary, Jiangsu Xuantai Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for a supplemental application regarding the extended-release tablets of Sitagliptin and Metformin [1] Group 1 - The approved supplemental application includes a new specification of "each tablet contains 50mg of Sitagliptin and 500mg of Metformin" [1] - The extended-release tablets are intended for adult patients with type 2 diabetes who are currently receiving a combination treatment of Sitagliptin and Metformin [1]